Search

Your search keyword '"Viale, A."' showing total 435 results
Start Over Author "Viale, A." Journal annals of oncology
435 results on '"Viale, A."'

2. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women

Author

Luen, S.J., Viale, G., Nik-Zainal, S., Savas, P., Kammler, R., Dell’Orto, P., Biasi, O., Degasperi, A., Brown, L.C., Láng, I., MacGrogan, G., Tondini, C., Bellet, M., Villa, F., Bernardo, A., Ciruelos, E., Karlsson, P., Neven, P., Climent, M., Müller, B., Joshum, W., Bonnefoi, H., Martino, S., Davidson, N.E., Geyer, C., Chia, S.K., Ingle, J.N., Coleman, R., Solbach, C., Thürlimann, B., Colleoni, M., Coates, A.S., Goldhirsch, A., Fleming, G.F., Francis, P.A., Speed, T.P., Regan, M.M., and Loi, S.

Published
2023
Full Text
View/download PDF

3. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

Author

Tarantino, P., Viale, G., Press, M.F., Hu, X., Llorca, F.P., Bardia, A., Batistatou, A., Burstein, H.J., Carey, L.A., Cortes, J., Denkert, C., Diéras, V., Jacot, W., Koutras, A.K., Lebeau, A., Loibl, S., Modi, S., Mosele, M.F., Provenzano, E., Pruneri, G., Reis Filho, J.S., Rojo, F., Salgado, R., Schmid, P., Schnitt, S.J., Tolaney, S.M., Trapani, D., Vincent-Salomon, A., Wolff, A.C., Pentheroudakis, G., André, F., and Curigliano, G.

Published
2023
Full Text
View/download PDF

4. Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy

Author

Jerusalem, G., Farah, S., Courtois, A., Chirgwin, J., Aebi, S., Karlsson, P., Neven, P., Hitre, E., Graas, M.P., Simoncini, E., Abdi, E., Kamby, C., Thompson, A., Loibl, S., Gavilá, J., Kuroi, K., Marth, C., Müller, B., O’Reilly, S., Gombos, A., Ruhstaller, T., Burstein, H.J., Rabaglio, M., Ruepp, B., Ribi, K., Viale, G., Gelber, R.D., Coates, A.S., Loi, S., Goldhirsch, A., Regan, M.M., and Colleoni, M.

Published
2021
Full Text
View/download PDF

5. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

Author

Aebi, Stephan, André, Fabrice, Barrios, Carlos, Bergh, Jonas, Bonnefoi, Herve, Bretel Morales, Denisse, Brucker, Sara, Burstein, Harold, Cameron, David, Cardoso, Fatima, Carey, Lisa, Chua, Boon, Ciruelos, Eva, Colleoni, Marco, Curigliano, Giuseppe, Delaloge, Suzette, Denkert, Carsten, Dubsky, Peter, Ejlertsen, Bent, Fitzal, Florian, Francis, Prudence, Galimberti, Viviana, Gamal El Din Mohamed Mahmoud, Hebatallah, Garber, Judy, Gnant, Michael, Gradishar, William, Gulluoglu, Bahadir, Harbeck, Nadia, Huang, Chiun-Sheng, Huober, Jens, Ilbawi, Andre, Jiang, Zefei, Johnston, Steven, Lee, Eun Sook, Loibl, Sibylle, Morrow, Monica, Partridge, Ann, Piccart, Martine, Poortmans, Philip, Prat, Aleix, Regan, Meredith, Rubio, Isabella, Rugo, Hope, Rutgers, Emiel, Sedlmayer, Felix, Semiglazov, Vladimir, Senn, Hans-Joerg, Shao, Zhiming, Spanic, Tanja, Tesarova, Petra, Thürlimann, Beat, Tjulandin, Sergei, Toi, Masakazu, Trudeau, Maureen, Turner, Nicholas, Vaz Luis, Inez, Viale, Giuseppe, Watanabe, Toru, Weber, Walter P., Winer, Eric P., Xu, Binghe, Burstein, H.J., Curigliano, G., Thürlimann, B., Weber, W.P., Poortmans, P., Regan, M.M., Senn, H.J., Winer, E.P., and Gnant, M.

Published
2021
Full Text
View/download PDF

8. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

Author

Bossuyt, V, Provenzano, E, Symmans, WF, Boughey, JC, Coles, C, Curigliano, G, Dixon, JM, Esserman, LJ, Fastner, G, Kuehn, T, Peintinger, F, von Minckwitz, G, White, J, Yang, W, Badve, S, Denkert, C, MacGrogan, G, Penault-Llorca, F, Viale, G, Cameron, D, collaboration, Breast International Group-North American Breast Cancer Group, Earl, Helena, Alba, Emilio, Lluch, Ana, Albanell, Joan, Amos, Keith, Biernat, Wojciech, Bonnefoi, Hervé, Buzdar, Aman, Cane, Paul, Pinder, Sarah, Carson, Lesley, Dickson-Witmer, Diana, Gong, Gyungyub, Green, Jimmy, Hsu, Chih-Yi, Tseng, Ling-Ming, Kroep, Judith, Leitch, A Marilyn, Sarode, Venetia, Mamounas, Eleftherios, Marcom, Paul Kelly, Nuciforo, Paolo, Paik, Soonmyung, Peg, Vicente, Peston, David, Pierga, Jean-Yves, Quintela-Fandino, Miguel, Salgado, Roberto, Sikov, William, Thomas, Jeremy, Unzeitig, Gary, and Wesseling, Jelle

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Breast Cancer, Cancer, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Clinical Trials as Topic, Female, Humans, Neoadjuvant Therapy, Neoplasm Staging, Neoplasm, Residual, Practice Guidelines as Topic, Prognosis, breast cancer, neoadjuvant systemic therapy, residual disease, pathologic complete response, pathologic assessment, response evaluation, Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

Neoadjuvant systemic therapy (NAST) provides the unique opportunity to assess response to treatment after months rather than years of follow-up. However, significant variability exists in methods of pathologic assessment of response to NAST, and thus its interpretation for subsequent clinical decisions. Our international multidisciplinary working group was convened by the Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration and tasked to recommend practical methods for standardized evaluation of the post-NAST surgical breast cancer specimen for clinical trials that promote accurate and reliable designation of pathologic complete response (pCR) and meaningful characterization of residual disease. Recommendations include multidisciplinary communication; clinical marking of the tumor site (clips); and radiologic, photographic, or pictorial imaging of the sliced specimen, to map the tissue sections and reconcile macroscopic and microscopic findings. The information required to define pCR (ypT0/is ypN0 or ypT0 yp N0), residual ypT and ypN stage using the current AJCC/UICC system, and the Residual Cancer Burden system were recommended for quantification of residual disease in clinical trials.

Published
2015

9. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

Author

Swain, S.M., Ewer, M.S., Viale, G., Delaloge, S., Ferrero, J.-M., Verrill, M., Colomer, R., Vieira, C., Werner, T.L., Douthwaite, H., Bradley, D., Waldron-Lynch, M., Kiermaier, A., Eng-Wong, J., and Dang, C.

Published
2018
Full Text
View/download PDF

10. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Author

C.E. Geyer, J.E. Garber, R.D. Gelber, G. Yothers, M. Taboada, L. Ross, P. Rastogi, K. Cui, A. Arahmani, G. Aktan, A.C. Armstrong, M. Arnedos, J. Balmaña, J. Bergh, J. Bliss, S. Delaloge, S.M. Domchek, A. Eisen, F. Elsafy, L.E. Fein, A. Fielding, J.M. Ford, S. Friedman, K.A. Gelmon, L. Gianni, M. Gnant, S.J. Hollingsworth, S.-A. Im, A. Jager, Ó. Þ Jóhannsson, S.R. Lakhani, W. Janni, B. Linderholm, T.-W. Liu, N. Loman, L. Korde, S. Loibl, P.C. Lucas, F. Marmé, E. Martinez de Dueñas, R. McConnell, K.-A. Phillips, M. Piccart, G. Rossi, R. Schmutzler, E. Senkus, Z. Shao, P. Sharma, C.F. Singer, T. Španić, E. Stickeler, M. Toi, T.A. Traina, G. Viale, G. Zoppoli, Y.H. Park, R. Yerushalmi, H. Yang, D. Pang, K.H. Jung, A. Mailliez, Z. Fan, I. Tennevet, J. Zhang, T. Nagy, G.S. Sonke, Q. Sun, M. Parton, M.A. Colleoni, M. Schmidt, A.M. Brufsky, W. Razaq, B. Kaufman, D. Cameron, C. Campbell, A.N.J. Tutt, Paul Sevelda, Ferdinand Haslbauer, Monika Penzinger, Leopold Öhler, Christoph Tinchon, Richard Greil, Sonja Heibl, Rupert Bartsch, Viktor Wette, Christian F. Singer, Claudia Pasterk, Ruth Helfgott, Gunda Pristauz-Telsnigg, Herbert Stöger, Angsar Weltermann, Daniel Egle, Irene Thiel, David Fuchs, Holger Rumpold, Kathrin Strasser-Weippl, Beate Rautenberg, Volkmar Müller, Marcus Schmidt, Stefan Paepke, Mustafa Aydogdu, Christoph Thomssen, Joachim Rom, Christine Mau, Peter Fasching, Uwe-Jochen Göhring, Thorsten Kühn, Stefanie Noeding, Sherko Kümmel, John Hackmann, Elmar Stickeler, Abhishek Joshi, Joanna Dewar, Michael Friedlander, Kelly-Anne Phillips, Yoland Antill, Natasha Woodward, Ehtesham Abdi, Susan Tiley, Mathew George, David Boadle, Annabel Goodwin, Andre van der Westhuizen, George Kannourakis, Nicholas Murray, Nicole McCarthy, Judith Kroep, Maaike de Boer, Joan Heijns, Agnes Jager, Franciscus Erdkamp, Sandra Bakker, Gabe S. Sonke, Amer Sami, John Mackey, Catherine Prady, Andrea Eisen, Christine Desbiens, Erica Patocskai, Cristiano Ferrario, Karen Gelmon, Louise Bordeleau, Haji Chalchal, Saroj Niraula, null ido wolf, Elżbieta Senkus, François Duhoux, null Randal d’Hondt, Sylvie Luce, Daphné t’Kint de Roodenbeke, Konstantinos Papadimitriou, Marleen Borms, Claire Quaghebeur, William Jacot, Etienne Brain, Laurence Venat-Bouvet, Alain Lortholary, Zbigniew Nowecki, Fátima Cardoso, Richard Hayward, Santiago Bella, Mauricio Fernández Lazzaro, Norma Pilnik, Luis E. Fein, Cesar Blajman, Guillermo Lerzo, Mirta Varela, Juan Jose Zarba, Diego Kaen, Maria Victoria Constanzo, Joke Tio, Wulf Siggelkow, Christian Jackisch, Eva Maria Grischke, Dirk Zahm, Sara Tato-Varela, Sabine Schmatloch, Peter Klare, Andrea Stefek, Kerstin Rhiem, Oliver Hoffmann, Mustafa Deryal, Isolde Gröll, Peter Ledwon, Christoph Uleer, Petra Krabisch, Jochem Potenberg, Maren Darsow, Tjoung-Won Park-Simon, Heinz-Gert Höffkes, Till-Oliver Emde, Gerd Graffunder, Oliver Tomé, Dirk Forstmeyer, Jürgen Terhaag, Christoph Salat, Karin Kast, Steffi Weniger, Carsten Schreiber, Bernhard Heinrich, Max Dieterich, Michaela Penelope Wüllner, Raquel Andrés Conejero, José Ángel García Sáenz, Lourdes Calvo Martinez, Angels Arcusa Lanza, Serafín Morales Murillo, Fernando Henao Carrasco, Salvador Blanch Tormo, Isabel Álvarez López, Juan Ignacio Delgado Mingorance, Elena Álvarez Gomez, Marta Santisteban, Josefina Cruz Jurado, Vanesa Quiroga, Manuel Ruiz Borrego, Eduardo Martínez de Dueñas, Jose Enrique Alés Martínez, Juan De la Haba, Noelia Martínez Jañez, Álvaro Rodríguez Lescure, Antonio Antón Torres, Gema Llort Crusades, Santiago González-Santiago, Antonia Marquez Aragones, Ana Laura Ortega, Agusti Barnadas Molins, José Ignacio Chacón López-Muñiz, Miguel Martín Jiménez, Ana Santaballa Bertrán, César Rodríguez, Lucía González Cortijo, Elisabetta Cretella, Laura Cortesi, Enzo Maria Ruggeri, Claudio Verusio, Stefania Gori, Andrea Bonetti, Anna Maria Mosconi, Oskar Johannsson, Guy Jerusalem, Patrick Neven, Tünde Nagy, Graziella Pinotti, Marco A. Colleoni, Antonio Bernardo, Lorenzo Gianni, Eraldo Bucci, Laura Biganzoli, Konstantin Dedes, Urban Novak, Khalil Zaman, Jeremy Braybrooke, Matthew Winter, Daniel Rea, Muireann Kelleher, Sophie Barrett, Stephen Chan, Tamas Hickish, Jane Hurwitz, John Conibear, Apurna Jegannathen, Marina Parton, Andrew Tutt, Rozenn Allerton, Annabel Borley, Anne Armstrong, Ellen Copson, Nicola Levitt, Jean Abraham, Timothy Perren, Rebecca Roylance, Kazushige Ishida, Tatsuya Toyama, Norikazu Masuda, Junichiro Watanabe, Eriko Tokunaga, Takayuki Kinoshita, Yoshiaki Rai, Masahiro Takada, Yasuhiro Yanagita, Rikiya Nakamura, Takahiro Nakayama, Yasuto Naoi, Hiroji Iwata, Seigo Nakamura, Masato Takahashi, Kenjiro Aogi, Koichiro Tsugawa, Hirofumi Mukai, Toshimi Takano, Akihiko Osaki, Nobuaki Sato, Hideko Yamauchi, Yutaka Tokuda, Mitsuya Ito, Takeki Sugimoto, Shakeela W. Bahadur, Patricia A. Ganz, Min J. Lu, Monica M. Mita, James Waisman, Jonathan A. Polikoff, Melinda L. Telli, Samantha A. Seaward, J. Marie Suga, Lara N. Durna, Jennifer Fu Carney, Alex Menter, Ajithkumar Puthillath, Nitin Rohatgi, James H. Feusner, Kristie A. Bobolis, Peter D. Eisenberg, Derrick Wong, Virginia F. Borges, Alexander T. Urquhart, Erin W. Hofstatter, Edward C. McCarron, Claudine Isaacs, Pia Herbolsheimer, Ramya Varadarajan, Adam Raben, Ruby Anne E. Deveras, Frances Valdes-Albini, Reshma L. Mahtani, Jane L. Meisel, Bradley T. Sumrall, Cheryl F. Jones, Samuel N. Ofori, Kenneth N.M. Sumida, Mark Karwal, Deborah W. Wilbur, (Joe) Singh, David M. Spector, John Schallenkamp, Douglas E. Merkel, Shelly S. Lo, Pam G. Khosla, Massimo Cristofanilli, Lisa Flaum, Kent F. Hoskins, Melody A. Cobleigh, Elyse A. Lambiase, Olwen M. Hahn, Ira A. Oliff, Bryan A. Faller, James L. Wade, Nafisa D. Burhani, Amaryllis Gil, Harvey E. Einhorn, Anna M.V. Storniolo, Brian K. Chang, Maitri Kalra, Erwin L. Robin, Bilal Ansari, Priyanka Sharma, Shaker R. Dakhil, Richard L. Deming, John T. Cole, David S. Hanson, Augusto C. Ochoa, Judy E. Garber, Harvey Zimbler, Deborah K. Armstrong, Katherine H.R. Tkaczuk, David A. Riseberg, Brian M. O'Connor, Thomas H. Openshaw, Dana Zakalik, Cynthia M. Vakhariya, Anne F. Schott, Michael S. Simon, Thomas J. Doyle, Tareq Al Baghdadi, Amy VanderWoude, Patrick J. Flynn, Richard T. Zera, Bret E.B. Friday, Kathryn J. Ruddy, Ron Smith, null Ademuyiwa, Foluso Olabisi, Robert Ellis, Jay W. Carlson, null Marchello, Benjamin T, Edward A. Levine, Paul K. Marcom, Cameron B. Harkness, Antoinette R. Tan, William J. Charles, Charles S. Kuzma, Shonda Asaad, James E. Radford, Preston D. Steen, Madhu Unnikrishnan, Grant R. Seeger, Kirsten M.H. Leu, Mehmet S. Copur, Ralph J. Hauke, Gamini S. Soori, Bradley A. Arrick, Jennifer G. Reeder, Deborah L. Toppmeyer, Zoneddy R. Dayao, Sylvia Adams, Eleni Andreopoulou, Magnuson Allison, Jesus D. Anampa Mesias, Ruby Sharma, Bhuvaneswari Ramaswamy, Aaron T. Gerds, Robert R. Shenk, Howard M. Gross, Shruti Trehan, Wajeeha Razaq, Abdul H. Mansoor, Christie J. Hilton, Adam M. Brufsky, Chanh Huynh, Nabila Chowdhury, Susan M. Domchek, Elin R. Sigurdson, Terrence P. Cescon, Marc A. Rovito, Albert S. DeNittis, Victor G. Vogel, Thomas B. Julian, L.E. Boyle, Luis Baez-Diaz, Frank J. Brescia, John E. Doster, Robert D. Siegel, Lucas Wong, Tejal Patel, Julie R. Nangia, Catherine A. Jones, George M. Cannon, Harry D. Bear, Hetal Vachhani, Mary Wilkinson, Marie E. Wood, Fengting Yan, Xingwei Sui, Carol M. van Haelst, Jennifer M. Specht, Ying Zhuo, Rubina Qamar, Matthew L. Ryan, Abigail Stockham, Shamsuddin Virani, Arlene A. Gayle, Steven J. Jubelirer, Sobha Kurian, Mohamad A. Salkeni, Niklas Loman, Barbro Linderholm, Gustav Silander, Anna-Lotta Hallbeck, Anna von Wachenfeldt Väppling, Elsa Curtit, Catarina Cardoso, Sofia Braga, Miguel Abreu, Mafalda Casa-Nova, Mónica Nave, Eva María Ciruelos Gil, Judith Balmaña Gelpi, Adela Fernández Ortega, Josep Gumà Padró, Begoña Bermejo de las Heras, María González Cao, Juan Cueva Bañuelos, Jesús Alarcon Company, Gemma Viñas Villaró, Laura García Estevez, Jens Huober, Steffi Busch, Tanja Fehm, Antje Hahn, Andrea Grafe, Thomas Noesselt, Thomas Dewitz, Harald Wagner, Christina Bechtner, Michael Weigel, Hans-Christian Kolberg, Thomas Decker, Jörg Thomalla, Tobias Hesse, Nadia Harbeck, Jan Schröder Jens-Uwe Blohmer, Marc Wolf Sütterlin, Renske Altena, Chang-Fang Chiu, Shin-Cheh Chen, Ming-Feng Hou, Yuan-Ching Chang, Shang-Hung Chen, Shou-Tung Chen, Chiun-Sheng Huang, Dah-Cherng Yeh, Jyh-Cherng Yu, Ling-Ming Tseng, Wei-Pang Chung, Audrey Mailliez, Thierry Petit, Suzette Delaloge, Christelle Lévy, Philippe Dalivoust, Jean-Marc Extra, Marie-Ange Mouret-Reynier, Anne-Claire Hardy-Bessard, Hélène Simon, Tiffenn L'Haridon, Alice Mege, Sylvie Giacchetti, Camille Chakiba-Brugere, Alain Gratet, Virginie Pottier, Jean-Marc Ferrero, Isabelle Tennevet, Christophe Perrin, Jean-Luc Canon, Sofie Joris, Zhimin Shao, Binghe Xu, ZeFei Jiang, Qiang Sun, Kunwei Shen, Da Pang, Jin Zhang, Shui Wang, Hongjian Yang, Ning Liao, Hong Zheng, Peifen Fu, Chuangui Song, Yongsheng Wang, Zhimin Fan, Cuizhi Geng, Olivier Tredan, László Landherr, Bella Kaufman, Rinat Yerushalmi, Beatrice Uziely, Pierfranco Conte, Claudio Zamagni, Giampaolo Bianchini, Michelino De Laurentiis, Carlo Tondini, Vittorio Gebbia, Mariangela Ciccarese, Tomasz Sarosiek, Jacek Mackiewicz, Anna Słowińska, Ewa Kalinka, Tomasz Huzarski, Seock-Ah Im, Kyung Hae Jung, Joo Hyuk Sohn, Jee Hyun Kim, Keun Seok Lee, Yeon Hee Park, Kyoung Eun Lee, Yee Soo Chae, Eun Kyung Cho, Institut Català de la Salut, [Geyer CE Jr] NRG Oncology/NSABP Foundation, Pittsburgh, USA. Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, USA. [Garber JE] Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. [Gelber RD] Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. Harvard T.H. Chan School of Public Health, Boston, USA. Frontier Science Foundation, Boston, USA. [Yothers G] NRG Oncology/NSABP Foundation, Pittsburgh, USA. Department of Biostatistics, University of Pittsburgh, Pittsburgh, USA. [Taboada M] Oncology Biometrics Department, AstraZeneca, Macclesfield, UK. [Ross L] Department of Data Management, Frontier Science (Scotland), Kincraig, Scotland, UK. [Balmaña J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Medical Oncology, Public Health, Virology, Department of Psychology, Education and Child Studies, Internal Medicine, General Practice, and Child and Adolescent Psychiatry / Psychology

Subjects
Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Medicaments antineoplàstics - Ús terapèutic, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Breast Neoplasms, Other subheadings::Other subheadings::/drug therapy [Other subheadings], olaparib, Article, breast cancer, SDG 3 - Good Health and Well-being, BRCA1/2, células::células germinativas [ANATOMÍA], Humans, Other subheadings::/therapeutic use [Other subheadings], Cells::Germ Cells [ANATOMY], neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], Otros calificadores::/uso terapéutico [Otros calificadores], BRCA1 Protein, PARP inhibition, acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS], adjuvant therapy, Hematology, Cèl·lules germinals, Germ Cells, Oncology, Mama - Càncer - Tractament, Phthalazines, Female, Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS]
Abstract

Adjuvant therapy; Breast cancer; Olaparib Terapia adyuvante; Cáncer de mama; Olaparib Teràpia adjuvant; Càncer de mama; Olaparib Background The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRCA2 (gBRCA1/2pv) and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer (EBC). The first pre-specified interim analysis (IA) previously demonstrated statistically significant improvement in invasive disease-free survival (IDFS) and distant disease-free survival (DDFS). The olaparib group had fewer deaths than the placebo group, but the difference did not reach statistical significance for overall survival (OS). We now report the pre-specified second IA of OS with updates of IDFS, DDFS, and safety. Patients and methods One thousand eight hundred and thirty-six patients were randomly assigned to olaparib or placebo following (neo)adjuvant chemotherapy, surgery, and radiation therapy if indicated. Endocrine therapy was given concurrently with study medication for hormone receptor-positive cancers. Statistical significance for OS at this IA required P < 0.015. Results With a median follow-up of 3.5 years, the second IA of OS demonstrated significant improvement in the olaparib group relative to the placebo group [hazard ratio 0.68; 98.5% confidence interval (CI) 0.47-0.97; P = 0.009]. Four-year OS was 89.8% in the olaparib group and 86.4% in the placebo group (Δ 3.4%, 95% CI −0.1% to 6.8%). Four-year IDFS for the olaparib group versus placebo group was 82.7% versus 75.4% (Δ 7.3%, 95% CI 3.0% to 11.5%) and 4-year DDFS was 86.5% versus 79.1% (Δ 7.4%, 95% CI 3.6% to 11.3%), respectively. Subset analyses for OS, IDFS, and DDFS demonstrated benefit across major subgroups. No new safety signals were identified including no new cases of acute myeloid leukemia or myelodysplastic syndrome. Conclusion With 3.5 years of median follow-up, OlympiA demonstrates statistically significant improvement in OS with adjuvant olaparib compared with placebo for gBRCA1/2pv-associated EBC and maintained improvements in the previously reported, statistically significant endpoints of IDFS and DDFS with no new safety signals. Funding for this work, which was conducted as a collaborative partnership among the Breast International Group, NRG Oncology, Frontier Science, AstraZeneca, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, U.S.A. (MSD), was provided by the National Institutes of Health (grant numbers: U10CA 180868, UG1CA 189867, and U10CA 180822) and by AstraZeneca as part of an alliance between AstraZeneca and MSD. Provision of olaparib and placebo was from AstraZeneca.

Published
2022

11. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

Author

Curigliano, G, Burstein, H.J., Winer, E.P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M.M., Piccart-Gebhart, M., Senn, H.-J., Thürlimann, B., André, F., Baselga, J., Bergh, J., Bonnefoi, H., Brucker, S.Y., Cardoso, F., Carey, L., Ciruelos, E., Cuzick, J., Denkert, C., Di Leo, A., Ejlertsen, B., Francis, P., Galimberti, V., Garber, J., Gulluoglu, B., Goodwin, P., Harbeck, N., Hayes, D.F., Huang, C.-S., Huober, J., Khaled, H., Jassem, J., Jiang, Z., Karlsson, P., Morrow, M., Orecchia, R., Osborne, K.C., Pagani, O., Partridge, A.H., Pritchard, K., Ro, J., Rutgers, E.J.T., Sedlmayer, F., Semiglazov, V., Shao, Z., Smith, I., Toi, M., Tutt, A., Viale, G., Watanabe, T., Whelan, T.J., and Xu, B.

Published
2017
Full Text
View/download PDF

14. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

Author

Coates, A.S., Winer, E.P., Goldhirsch, A., Gelber, R.D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., André, Fabrice, Baselga, José, Bergh, Jonas, Bonnefoi, Hervé, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Coates, Alan S., Colleoni, Marco, Curigliano, Giuseppe, Davidson, Nancy E., Di Leo, Angelo, Ejlertsen, Bent, Forbes, John F., Galimberti, Viviana, Gelber, Richard D., Gnant, Michael, Goldhirsch, Aron, Goodwin, Pamela, Harbeck, Nadia, Hayes, Daniel F., Huober, Jens, Hudis, Clifford A., Ingle, James N., Jassem, Jacek, Jiang, Zefei, Karlsson, Per, Morrow, Monica, Orecchia, Roberto, Kent Osborne, C., Partridge, Ann H., de la Peña, Lorena, Piccart-Gebhart, Martine J., Pritchard, Kathleen I., Rutgers, Emiel J.T., Sedlmayer, Felix, Semiglazov, Vladimir, Shao, Zhi-Ming, Smith, Ian, Thürlimann, Beat, Toi, Masakazu, Tutt, Andrew, Viale, Giuseppe, von Minckwitz, Gunter, Watanabe, Toru, Whelan, Timothy, Winer, Eric P., and Xu, Binghe

Published
2015
Full Text
View/download PDF

15. Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy

Author

Richard D. Gelber, Erika Hitre, Andrea Gombos, Alan S. Coates, Alastair M. Thompson, Sole Investigators, Barbara Ruepp, J Chirgwin, Bettina Müller, Marie-Pascale Graas, Stefan Aebi, Subrina Farah, Joaquín Gavilá, Patrick Neven, K. Ribi, A Courtois, Christian Marth, E Abdi, Per Karlsson, Harold J. Burstein, Katsumasa Kuroi, Seamus O'Reilly, A. Goldhirsch, Thomas Ruhstaller, S. Loibl, Manuela Rabaglio, Marco Colleoni, G. Jerusalem, Giulia Viale, C Kamby, Sherene Loi, Edda Simoncini, and Meredith M. Regan

Subjects
medicine.medical_specialty, medicine.drug_class, medicine.medical_treatment, Population, Urology, Breast Neoplasms, Disease-Free Survival, Breast cancer, Nitriles, medicine, Humans, 610 Medicine & health, Adverse effect, education, education.field_of_study, Aromatase Inhibitors, business.industry, Letrozole, Hazard ratio, Estrogens, Hematology, Triazoles, medicine.disease, Confidence interval, Postmenopause, Tamoxifen, Receptors, Estrogen, Oncology, Chemotherapy, Adjuvant, Estrogen, Female, Receptors, Progesterone, business, Adjuvant, medicine.drug
Abstract

BACKGROUND Late recurrences in postmenopausal women with hormone receptor-positive breast cancers remain an important challenge. Avoidance or delayed development of resistance represents the main objective in extended endocrine therapy (ET). In animal models, resistance was reversed with restoration of circulating estrogen levels during interruption of letrozole treatment. This phase III, randomized, open-label Study of Letrozole Extension (SOLE) studied the effect of extended intermittent letrozole treatment in comparison with continuous letrozole. In parallel, the SOLE estrogen substudy (SOLE-EST) analyzed the levels of estrogen during the interruption of treatment. PATIENTS AND METHODS SOLE enrolled 4884 postmenopausal women with hormone receptor-positive, lymph node-positive, operable breast cancer between December 2007 and October 2012 and among them, 104 patients were enrolled in SOLE-EST. They must have undergone local treatment and have completed 4-6 years of adjuvant ET. Patients were randomized between continuous letrozole (2.5 mg/day orally for 5 years) and intermittent letrozole treatment (2.5 mg/day for 9 months followed by a 3-month interruption in years 1-4 and then 2.5 mg/day during all of year 5). RESULTS Intention-to-treat population included 4851 women in SOLE (n��= 2425 in the intermittent and n��= 2426 in the continuous letrozole groups) and 103 women in SOLE-EST (n��= 78 in the intermittent and n��= 25 in the continuous letrozole groups). After a median follow-up of 84 months, 7-year disease-free survival (DFS) was 81.4% in the intermittent group and 81.5% in the continuous group (hazard ratio: 1.03, 95% confidence interval: 0.91-1.17). Reported adverse events were similar in both groups. Circulating estrogen recovery was demonstrated within 6 weeks after the stop of letrozole treatment. CONCLUSIONS Extended adjuvant ET by intermittent administration of letrozole did not improve DFS compared with continuous use, despite the recovery of circulating estrogen levels. The similar DFS coupled with previously reported quality-of-life advantages suggest intermittent extended treatment is a valid option for patients who require or prefer a treatment interruption.

Published
2021

16. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

Author

H.J. Burstein, G. Curigliano, B. Thürlimann, W.P. Weber, P. Poortmans, M.M. Regan, H.J. Senn, E.P. Winer, M. Gnant, Stephan Aebi, Fabrice André, Carlos Barrios, Jonas Bergh, Herve Bonnefoi, Denisse Bretel Morales, Sara Brucker, Harold Burstein, David Cameron, Fatima Cardoso, Lisa Carey, Boon Chua, Eva Ciruelos, Marco Colleoni, Giuseppe Curigliano, Suzette Delaloge, Carsten Denkert, Peter Dubsky, Bent Ejlertsen, Florian Fitzal, Prudence Francis, Viviana Galimberti, Hebatallah Gamal El Din Mohamed Mahmoud, Judy Garber, Michael Gnant, William Gradishar, Bahadir Gulluoglu, Nadia Harbeck, Chiun-Sheng Huang, Jens Huober, Andre Ilbawi, Zefei Jiang, Steven Johnston, Eun Sook Lee, Sibylle Loibl, Monica Morrow, Ann Partridge, Martine Piccart, Philip Poortmans, Aleix Prat, Meredith Regan, Isabella Rubio, Hope Rugo, Emiel Rutgers, Felix Sedlmayer, Vladimir Semiglazov, Hans-Joerg Senn, Zhiming Shao, Tanja Spanic, Petra Tesarova, Beat Thürlimann, Sergei Tjulandin, Masakazu Toi, Maureen Trudeau, Nicholas Turner, Inez Vaz Luis, Giuseppe Viale, Toru Watanabe, Walter P. Weber, Eric P. Winer, Binghe Xu, and Panelists of the St Gallen Consensus Conference

Subjects
medicine.medical_specialty, medicine.diagnostic_test, business.industry, medicine.medical_treatment, media_common.quotation_subject, Hematology, medicine.disease, Radiation therapy, Presentation, Breast cancer, Oncology, Multidisciplinary approach, Family medicine, Pandemic, medicine, Human medicine, business, Neoadjuvant therapy, media_common, Early breast cancer, Genetic testing
Abstract

The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this important bi-annual critical review of the 'state of the art' in the multidisciplinary care of early-stage breast cancer. Seventy-four expert panelists (see Appendix 1) from all continents discussed and commented on the previously elaborated consensus questions, as well as many key questions on early breast cancer diagnosis and treatment asked by the audience. The theme of this year's conference was 'Customizing local and systemic therapies.' A well-organized program of pre-recorded symposia, live panel discussions and real-time panel voting results drew a worldwide audience of thousands, reflecting the farreaching impact of breast cancer on every continent. The interactive technology platform allowed, for the first time, audience members to ask direct questions to panelists, and to weigh in with their own vote on several key panel questions. A hallmark of this meeting was to focus on customized recommendations for treatment of early-stage breast cancer. There is increasing recognition that the care of a breast cancer patient depends on highly individualized clinical features, including the stage at presentation, the biological subset of breast cancer, the genetic factors that may underlie breast cancer risk, the genomic signatures that inform treatment recommendations, the extent of response before surgery in patients who receive neoadjuvant therapy, and patient preferences. This customized approach to treatment requires integration of clinical care between patients and radiology, pathology, genetics, and surgical, medical and radiation oncology providers. It also requires a dynamic response from clinicians as they encounter accumulating clinical information at the time of diagnosis and then serially with each step in the treatment plan and follow-up, reflecting patient experiences and treatment response.

Published
2021

18. 139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial

Author

Rediti, M., primary, Venet, D., additional, Joaquin Garcia, A., additional, Agbor-tarh, D., additional, Maetens, M., additional, Vincent, D., additional, Majjaj, S., additional, El-Abed, S., additional, Liu, M.C., additional, Di Cosimo, S., additional, Piccart, M., additional, Pusztai, L., additional, Loi, S., additional, Salgado, R.F., additional, Viale, G., additional, Rothé, F., additional, and Sotiriou, C., additional

Published
2022
Full Text
View/download PDF

20. VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up

Author

Loibl, S., primary, Jassem, J., additional, Sonnenblick, A., additional, Parlier, D., additional, Winer, E., additional, Bergh, J., additional, Gelber, R.D., additional, Restuccia, E., additional, Im, Y-H., additional, Huang, C., additional, Dalenc, F., additional, Calvo, I., additional, Procter, M., additional, Caballero, C., additional, Clark, E., additional, Gomez Moreno, H.L., additional, Bliss, J., additional, Viale, G., additional, Bines, J., additional, and Piccart, M., additional

Published
2022
Full Text
View/download PDF

24. LBA21 Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)

Author

Salgado, R.F., Bardia, A., Curigliano, G., Hu, X., Dent, R.A., Pierga, J-Y., Tsurutani, J., Wildiers, H., Ricciardi, G.R.R., Marchiò, C., Penault-Llorca, F., Bor-Angelier, C., Andrzejuk-Cwik, A., Darilay, A., Matsuo, T., Shami, R., Jones, F., and Viale, G.

Published
2024
Full Text
View/download PDF

25. LBA18 Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results

Author

Lin, N., Ciruelos, E.M., Jerusalem, G., Mueller, V., Niikura, N., Viale, G., Bartsch, R., Kurzeder, C., Connolly, R., Baron-Hay, S.E., Gion Cortes, M., Guarneri, V., Bianchini, G., Wildiers, H., Escrivá-de-Romaní, S., Prahladan, M., Bridge, H., Verma, S., and Harbeck, N.

Published
2024
Full Text
View/download PDF

26. Reply to ‘The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology’ by Kirova et al.

Author

Dubsky, P, Curigliano, G, Burstein, H J, Winer, E P, Gnant, M, Loibl, S, Colleoni, M, Regan, M M, Piccart-Gebhart, M, Senn, H -J, Thürlimann, B, André, F, Baselga, J, Bergh, J, Bonnefoi, H, Brucker, S Y, Cardoso, F, Carey, L, Ciruelos, E, Cuzick, J, Denkert, C, Di Leo, A, Ejlertsen, B, Francis, P, Galimberti, V, Garber, J, Gulluoglu, B, Goodwin, P, Harbeck, N, Hayes, D F, Huang, C -S, Huober, J, Khaled, H, Jassem, J, Jiang, Z, Karlsson, P, Morrow, M, Orecchia, R, Osborne, K C, Pagani, O, Partridge, A H, Pritchard, K, Ro, J, Rutgers, E J T, Sedlmayer, F, Semiglazov, V, Shao, Z, Smith, I, Toi, M, Tutt, A, Viale, G, Watanabe, T, Whelan, T J, and Xu, B

Published
2018
Full Text
View/download PDF

31. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Author

Gianni, L., primary, Huang, C.S., additional, Egle, D., additional, Bermejo, B., additional, Zamagni, C., additional, Thill, M., additional, Anton, A., additional, Zambelli, S., additional, Bianchini, G., additional, Russo, S., additional, Ciruelos, E.M., additional, Greil, R., additional, Semiglazov, V., additional, Colleoni, M., additional, Kelly, C., additional, Mariani, G., additional, Del Mastro, L., additional, Maffeis, I., additional, Valagussa, P., additional, and Viale, G., additional

Published
2022
Full Text
View/download PDF

32. 29P The molecular landscape of breast mucoepidermoid carcinoma

Author

Fusco, N., primary, Venetis, K., additional, Sajjadi, E., additional, Ivanova, M., additional, Andaloro, S., additional, Pessina, S., additional, Zanetti, C., additional, Citelli, G., additional, Rossi, C., additional, Lucioni, M., additional, Malapelle, U., additional, Pagni, F., additional, Barberis, M., additional, Guerini-Rocco, E., additional, and Viale, G., additional

Published
2022
Full Text
View/download PDF

33. 22P Biobanking in breast cancer: 10 years of practice at the European Institute of Oncology

Author

Viale, G., primary, Bonizzi, G., additional, Capra, M., additional, Zattoni, L., additional, Cassi, C., additional, Taliento, G., additional, Sajjadi, E., additional, Guerini-Rocco, E., additional, Colleoni, M.A., additional, Galimberti, V., additional, Veronesi, P., additional, Curigliano, G., additional, Orecchia, R., additional, and Fusco, N., additional

Published
2022
Full Text
View/download PDF

49. Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer

Author

Viale, G., Giobbie-Hurder, A., Gusterson, B.A., Maiorano, E., Mastropasqua, M.G., Sonzogni, A., Mallon, E., Colleoni, M., Castiglione-Gertsch, M., Regan, M.M., Price, K.N., Brown, R.W., Golouh, R., Crivellari, D., Karlsson, P., Öhlschlegel, C., Gelber, R.D., Goldhirsch, A., and Coates, A.S.

Published
2010
Full Text
View/download PDF

50. Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment

Author

Eleonora Pagan, A. Goldhirsch, Giulia Viale, Vincenzo Bagnardi, R. D. Gelber, T. De Pas, Fabio Conforti, Laura Pala, Conforti, F, Pala, L, Bagnardi, V, Viale, G, De Pas, T, Pagan, E, Gelber, R, and Goldhirsch, A

Subjects
Male, Mutation rate, T-Lymphocytes, T cell, Inflammation, Drug resistance, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Sex Factors, Mutation Rate, Predictive Value of Tests, Neoplasms, Biomarkers, Tumor, Tumor Microenvironment, medicine, Humans, Tumor microenvironment, biology, business.industry, Health Status Disparities, Hematology, Prognosis, Tumor mutational burden, Treatment Outcome, medicine.anatomical_structure, Oncology, Drug Resistance, Neoplasm, Predictive value of tests, Monoclonal, Cancer research, biology.protein, Female, medicine.symptom, Antibody, business
Published
2019

Catalog

Books, media, physical & digital resources
See catalog results